Tower Research Capital (TRC)’s Addex Therapeutics ADXN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6	Closed	–	–	5840
2022 Q3	$0	Buy	+6	New	+$134	﹤0.01%	6018
2021 Q1	–	Sell	-2	Closed	-$1K	–	5354
2020 Q4	$1K	Buy	+2	New	+$496	﹤0.01%	4970

Other funds holding ADXN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Tower Research Capital (TRC)'s ADXN Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Addex Therapeutics (ADXN) in Q4 2022, closing a stake of 6 shares.

Tower Research Capital (TRC) first reported a position in ADXN in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q4 2020. 8 funds tracked by Wall St. Rank hold ADXN as of Q4 2022.

Tower Research Capital (TRC) reported no remaining Addex Therapeutics position as of Q4 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 6 Addex Therapeutics shares in Q4 2022.
Tower Research Capital (TRC) first reported a position in Addex Therapeutics in Q4 2020 and held it in 2 quarters.
Tower Research Capital (TRC)'s Addex Therapeutics position peaked at $1K in Q4 2020.
8 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.